ARID1A Mutation in Metastatic Breast Cancer: A Potential Therapeutic Target

Distant metastasis is the principal cause of mortality for breast cancer patients. Targeting specific mutations that have been acquired during the evolution process of advanced breast cancer is a potential means of enhancing the clinical efficacy of treatment strategies. In metastatic breast cancer,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Xuan Cheng, Jian-Xiong Zhao, Feng Dong, Xu-Chen Cao
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	ARID1A metastatic breast cancer SWI/SNF complex endocrine resistance synthetic lethality therapeutic targets Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/cb7b9d2bd5ac409393c064b6b03f2372
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cb7b9d2bd5ac409393c064b6b03f2372
record_format	dspace
spelling	oai:doaj.org-article:cb7b9d2bd5ac409393c064b6b03f23722021-11-04T06:28:58ZARID1A Mutation in Metastatic Breast Cancer: A Potential Therapeutic Target2234-943X10.3389/fonc.2021.759577https://doaj.org/article/cb7b9d2bd5ac409393c064b6b03f23722021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fonc.2021.759577/fullhttps://doaj.org/toc/2234-943XDistant metastasis is the principal cause of mortality for breast cancer patients. Targeting specific mutations that have been acquired during the evolution process of advanced breast cancer is a potential means of enhancing the clinical efficacy of treatment strategies. In metastatic breast cancer, ARID1A is the most prevalent mutation of the SWI/SNF complex, which regulates DNA repair, recombination, and gene transcription. The low expression of ARID1A is associated with poor disease-free survival and overall survival of patients with luminal A or HER2-rich breast cancer. In addition, ARID1A plays a prominent role in maintaining luminal characteristics and has an advantage for identifying responses to treatment, including endocrine therapies, HDAC inhibitors and CDK4/6 inhibitors. The therapeutic vulnerabilities initiated by ARID1A alterations encourage us to explore new approaches to cope with ARID1A mutant-related drug resistance or metastasis. In this review, we describe the mutation profiles of ARID1A in metastatic breast cancer and the structure and function of ARID1A and the SWI/SNF complex as well as discuss the potential mechanisms of ARID1A-mediated endocrine resistance and therapeutic potential.Xuan ChengXuan ChengXuan ChengXuan ChengJian-Xiong ZhaoJian-Xiong ZhaoJian-Xiong ZhaoJian-Xiong ZhaoFeng DongFeng DongXu-Chen CaoXu-Chen CaoXu-Chen CaoXu-Chen CaoFrontiers Media S.A.articleARID1Ametastatic breast cancerSWI/SNF complexendocrine resistancesynthetic lethalitytherapeutic targetsNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENFrontiers in Oncology, Vol 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	ARID1A metastatic breast cancer SWI/SNF complex endocrine resistance synthetic lethality therapeutic targets Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	ARID1A metastatic breast cancer SWI/SNF complex endocrine resistance synthetic lethality therapeutic targets Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Xuan Cheng Xuan Cheng Xuan Cheng Xuan Cheng Jian-Xiong Zhao Jian-Xiong Zhao Jian-Xiong Zhao Jian-Xiong Zhao Feng Dong Feng Dong Xu-Chen Cao Xu-Chen Cao Xu-Chen Cao Xu-Chen Cao ARID1A Mutation in Metastatic Breast Cancer: A Potential Therapeutic Target
description	Distant metastasis is the principal cause of mortality for breast cancer patients. Targeting specific mutations that have been acquired during the evolution process of advanced breast cancer is a potential means of enhancing the clinical efficacy of treatment strategies. In metastatic breast cancer, ARID1A is the most prevalent mutation of the SWI/SNF complex, which regulates DNA repair, recombination, and gene transcription. The low expression of ARID1A is associated with poor disease-free survival and overall survival of patients with luminal A or HER2-rich breast cancer. In addition, ARID1A plays a prominent role in maintaining luminal characteristics and has an advantage for identifying responses to treatment, including endocrine therapies, HDAC inhibitors and CDK4/6 inhibitors. The therapeutic vulnerabilities initiated by ARID1A alterations encourage us to explore new approaches to cope with ARID1A mutant-related drug resistance or metastasis. In this review, we describe the mutation profiles of ARID1A in metastatic breast cancer and the structure and function of ARID1A and the SWI/SNF complex as well as discuss the potential mechanisms of ARID1A-mediated endocrine resistance and therapeutic potential.
format	article
author	Xuan Cheng Xuan Cheng Xuan Cheng Xuan Cheng Jian-Xiong Zhao Jian-Xiong Zhao Jian-Xiong Zhao Jian-Xiong Zhao Feng Dong Feng Dong Xu-Chen Cao Xu-Chen Cao Xu-Chen Cao Xu-Chen Cao
author_facet	Xuan Cheng Xuan Cheng Xuan Cheng Xuan Cheng Jian-Xiong Zhao Jian-Xiong Zhao Jian-Xiong Zhao Jian-Xiong Zhao Feng Dong Feng Dong Xu-Chen Cao Xu-Chen Cao Xu-Chen Cao Xu-Chen Cao
author_sort	Xuan Cheng
title	ARID1A Mutation in Metastatic Breast Cancer: A Potential Therapeutic Target
title_short	ARID1A Mutation in Metastatic Breast Cancer: A Potential Therapeutic Target
title_full	ARID1A Mutation in Metastatic Breast Cancer: A Potential Therapeutic Target
title_fullStr	ARID1A Mutation in Metastatic Breast Cancer: A Potential Therapeutic Target
title_full_unstemmed	ARID1A Mutation in Metastatic Breast Cancer: A Potential Therapeutic Target
title_sort	arid1a mutation in metastatic breast cancer: a potential therapeutic target
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/cb7b9d2bd5ac409393c064b6b03f2372
work_keys_str_mv	AT xuancheng arid1amutationinmetastaticbreastcancerapotentialtherapeutictarget AT xuancheng arid1amutationinmetastaticbreastcancerapotentialtherapeutictarget AT xuancheng arid1amutationinmetastaticbreastcancerapotentialtherapeutictarget AT xuancheng arid1amutationinmetastaticbreastcancerapotentialtherapeutictarget AT jianxiongzhao arid1amutationinmetastaticbreastcancerapotentialtherapeutictarget AT jianxiongzhao arid1amutationinmetastaticbreastcancerapotentialtherapeutictarget AT jianxiongzhao arid1amutationinmetastaticbreastcancerapotentialtherapeutictarget AT jianxiongzhao arid1amutationinmetastaticbreastcancerapotentialtherapeutictarget AT fengdong arid1amutationinmetastaticbreastcancerapotentialtherapeutictarget AT fengdong arid1amutationinmetastaticbreastcancerapotentialtherapeutictarget AT xuchencao arid1amutationinmetastaticbreastcancerapotentialtherapeutictarget AT xuchencao arid1amutationinmetastaticbreastcancerapotentialtherapeutictarget AT xuchencao arid1amutationinmetastaticbreastcancerapotentialtherapeutictarget AT xuchencao arid1amutationinmetastaticbreastcancerapotentialtherapeutictarget
_version_	1718445116578856960

ARID1A Mutation in Metastatic Breast Cancer: A Potential Therapeutic Target

Ejemplares similares